Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 211 - 220 of 1165

Yesintek (ustekinumab)

Status:

Concluded with an LOI

Manufacturer:

Biocon Biologics Canada Inc.

Indication:

Multiple Indications

Last updated September 16, 2025

Otulfi (ustekinumab)

Status:

Concluded with an LOI

Manufacturer:

Fresenius Kabi Canada Ltd.

Indication:

Multiple Indications

Last updated September 16, 2025

Opdivo (nivolumab)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

With doxorubicin, vinblastine and dacarbazine (AVD) in previously untreated stage III or IV Hodgkin Lymphoma.

Last updated September 4, 2025

Rystiggo (rozanolixizumab)

Status:

Concluded with an LOI

Manufacturer:

UCB Canada Inc.

Indication:

Generalized myasthenia gravis (gMG)

Last updated August 29, 2025

Idenos (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Apotex Inc.

Indication:

Multiple Indications

Last updated August 29, 2025

Osdenza (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Apotex Inc.

Indication:

Osteoporosis

Last updated August 29, 2025

Zilbrysq (zilucoplan)

Status:

Concluded with an LOI

Manufacturer:

UCB Canada Inc.

Indication:

Generalized myasthenia gravis (gMG)

Last updated August 29, 2025

Bilprevda (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Organon Canada Inc.

Indication:

Multiple Indications

Last updated August 28, 2025

Bildyos (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Organon Canada Inc.

Indication:

Multiple Indications

Last updated August 28, 2025

Ebglyss (lebrikizumab)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

Atopic dermatitis

Last updated August 28, 2025